Article Text

Download PDFPDF
Disseminated Mycobacterium chelonae infection in kidney transplant patients
  1. Mustafa Muwafaq Yaseen1,
  2. Sebastian Spencer2 and
  3. Sunil Bhandari2
  1. 1Hull University Teaching Hospitals NHS Trust, Hull, East Riding of Yorkshire, UK
  2. 2Nephrology, Hull University Teaching Hospitals NHS Trust, Hull, East Riding of Yorkshire, UK
  1. Correspondence to Dr Mustafa Muwafaq Yaseen; mustafamoufaq{at}gmail.com

Abstract

Mycobacterium chelonae (M. chelonae) is a member of the rapidly growing non-tuberous mycobacteria and can cause disseminated tissue infection, particularly, in the limbs. We reviewed medical records of two kidney transplant patients. We describe their background disease and transplantation details, with the use of immunosuppressive medication. We also discuss the presentation of M. chelonae infection and treatment. Both patients received deceased brain-dead donor kidney transplants for end-stage kidney disease. Both developed cutaneous manifestations of M. chelonae, progressing to disseminated infections. Case 1 was on low-dose prednisolone (2 mg) and tacrolimus, whereas, case 2 received varying doses of prednisolone (5–40 mg) and sirolimus. Antibiotics advised by infectious disease specialists were initiated within a month of skin lesion appearance. Effective treatment involved a combination of antibiotics such as clarithromycin, azithromycin, linezolid and tigecycline. These cases underline the efficacy of clarithromycin and azithromycin as long-term antibiotic treatment, with linezolid and tigecycline for management of acute dissemination.

  • Renal system
  • Renal transplantation
  • Infectious diseases

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors The following authors were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, and critical revision for important intellectual content: all authors SB, SS and MY. The following authors gave final approval of the manuscript: SB, SS and MY. AI was used from grammar and proofreading.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.